Word

AIONCO

Status

Dead

Status Code

602

Status Date

Friday, March 15, 2024

Serial Number

97646050

Mark Type

3000

Filing Date

Monday, October 24, 2022

Abandoned Date

Monday, February 12, 2024

Trademark Owner History

Avellino Lab USA, Inc.

Classifications

9 Downloadable software and mobile applications for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating local databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping; medical testing products, namely, downloadable vaccination test forms

5 Medical testing products, namely, modified immune cells; Medical testing products, namely, modified immune cells for use in connection with various cancers with genetic treatments

16 Medical testing and treatment products, namely, printed test forms and printed user information inserts for medical products; Medical testing products, namely, printed vaccination test forms

44 Providing medical diagnostic and treatment services, namely, tumor detection in the form of a liquid biopsy; medical diagnostic and treatment services in the nature of tumor analysis, diagnosis, and identification in the form of sequenced tissue identification, and tumor medical treatment therapy in the form of identification of appropriate combination of mutations for targeted cancers and identification of appropriate treatments targeted for those combination of mutations via modified T-Cells in the form of other treatments to inhibit expressions of those combination of mutations and to modify one or more of the mutations in the combination

10 Medical testing and treatment products in the form of treatment therapies, namely, apparatus for medical diagnosis, drug delivery apparatus and genetic delivery apparatus all for various cancers with genetic treatments and specimen collection tubes and containers for collecting patient specimens, namely, blood, urine, saliva, and tissue, for genomic sequencing and for detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer; Medical testing and treatment product kits containing blood specimen collection tubes and containers for collecting patient blood specimens for genomic sequencing and detection of gene mutations, gene expression profiles or other molecular indicators or markers associated with cancer or risk of developing cancer modified immune cells and treatment therapies, and also containing modified immune cells, treatment therapies, test forms, mailing materials and user information inserts

42 Providing online non-downloadable software and software programs for genetic assessment and identification of cancer, cancer ailments, and cancer mutations for scientific, medical, diagnostic, treatment, and research purposes, for creating online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for creating, accessing, and using online databases of genomic sequences, cancer ailments, and cancer mutations for tracking, matching, searching, testing, aggregating, researching, and diagnosing cancer, cancer ailments, and cancer mutations, for recording, analyzing, storing, manipulating and organizing genetic and molecular data, and for providing access to multiple online databases that contain aggregated results of molecular biology testing and genotyping

The mark consists of a circle which is circumscribed appearing next to the word "AIONCO" in a stylized font resembling a DNA sequence in orange and red color. Within the ring of the circle are other circles layered together with colors blue and teal. The background is transparent. White is not claimed as a color of the mark.
The color(s) blue, teal, orange and red is/are claimed as a feature of the mark.

Trademark Events

Mar 15, 2024

Abandonment Notice E-Mailed - Failure To Respond

Mar 15, 2024

Abandonment - Failure To Respond Or Late Response

Nov 10, 2023

Application Extension Granted/Receipt Provided

Nov 10, 2023

Application Extension To Response Period - Received

Aug 11, 2023

Notification Of Non-Final Action E-Mailed

Aug 11, 2023

Non-Final Action E-Mailed

Aug 11, 2023

Non-Final Action Written

Aug 7, 2023

Assigned To Examiner

Nov 9, 2022

Notice Of Design Search Code E-Mailed

Nov 8, 2022

New Application Office Supplied Data Entered

Oct 27, 2022

New Application Entered